Corticosteroids Market Size & Growth Forecast 2026–2035, By Segments (Product, Distribution Channel, Route of Administration, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Corticosteroids Market size was around USD 5.83 Billion in 2025 and is slated to grow at a 5.6% CAGR from 2026 to 2035, crossing USD 10.05 Billion by 2035. The industry revenue for 2026 is calculated at USD 6.11 billion.

• Base Year Value (2025): USD 5.83 Billion
• CAGR (2026-2035): 5.6%
• Forecast Year Value (2035): USD 10.05 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Corticosteroids Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads through established prescribing patterns, specialist access, mature healthcare systems, and consistent use of therapies across inflammatory and autoimmune conditions.
  • Asia Pacific is projected to grow at a 6.33% CAGR, supported by improving healthcare access, broader therapy availability, and rising treatment uptake.

• Segment Momentum:

  • Hospital Pharmacies lead the market because corticosteroid therapies are frequently initiated, adjusted, and monitored in inpatient and specialist care settings where physician oversight is essential.
  • Online Pharmacies are the fastest-growing channel, supported by growing demand for convenient prescription fulfillment, home delivery, and easier refill access for ongoing corticosteroid therapies.

• Market Expansion Drivers:

  • Rising global cancer incidence increasing corticosteroid use for inflammation and symptom management.
  • Expanding healthcare expenditure improving access to treatments for autoimmune and respiratory disorders.
  • Growing adoption of corticosteroid therapies in critical respiratory care strengthening hospital demand volumes.

• Industry Adoption Constraints:

• Leading Market Participants:

  Prominent players in the corticosteroids market include Pfizer Inc. (U.S.), Novartis AG (Switzerland), AstraZeneca PLC (U.K.), GSK plc (U.K.), Merck KGaA (Germany), Abbott Laboratories (U.S.), Cipla Limited (India), Eli Lilly and Company (U.S.), Sanofi S.A. (France), ReveraGen BioPharma, Inc. (U.S.).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 5.83 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 10.05 Billion by 2035
  • Growth Forecasts: 5.6% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Glucocorticoids (Product) | Hospital Pharmacies (Distribution Channel) | Inhaled (Route of Administration) | Respiratory Disorders (Application)
  • Emerging Opportunity Segment: Mineralocorticoids (Product) | Online Pharmacies (Distribution Channel) | Injectable (Route of Administration) | Autoimmune Diseases (Application)

Market Growth Drivers and Industry Trends

Rising global cancer incidence increasing corticosteroid use for inflammation and symptom management

As cancer incidence rises globally, corticosteroids are being used more routinely as supportive therapies to control inflammation, reduce edema, manage treatment-related side effects, and improve patient tolerance during chemotherapy, radiation, and palliative care. This pattern is increasing demand for the corticosteroids market because oncology care pathways often require corticosteroids not as one-time interventions but as repeated adjunct treatments integrated into broader treatment regimens. Their role in symptom management also reinforces prescribing continuity in hospital and specialty care settings, where clinicians rely on familiar, fast-acting agents to stabilize patients and maintain treatment schedules.

Expanding healthcare expenditure improving access to treatments for autoimmune and respiratory disorders

Higher healthcare spending is improving diagnosis rates, treatment access, and prescription continuity for chronic autoimmune and respiratory conditions, all of which are closely tied to corticosteroid utilization. In the corticosteroids market, this translates into stronger uptake through better-funded hospitals, wider insurance coverage, expanded outpatient care, and more consistent availability of essential therapies. As health systems allocate more resources to chronic disease management, physicians are more likely to initiate and sustain corticosteroid-based treatment plans for flare control and symptom suppression, aiding market expansion through broader patient reach and steadier treatment volumes.

Growing adoption of corticosteroid therapies in critical respiratory care strengthening hospital demand volumes

In critical respiratory care, corticosteroids are increasingly embedded in hospital treatment protocols for severe inflammatory lung conditions and acute exacerbations that require rapid intervention. This is driving market development for the corticosteroids market because hospital procurement is shaped by protocol-led, volume-based purchasing, especially for injectable formulations used in intensive and emergency care. As clinicians prioritize therapies that can quickly reduce airway inflammation and support stabilization, hospitals maintain dependable stocking and replenishment cycles, increasing market adoption through institutional demand rather than discretionary outpatient use.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global cancer incidence increasing corticosteroid use for inflammation and symptom management	2.10%	High	Asia Pacific, North America	High	Near Term
Expanding healthcare expenditure improving access to treatments for autoimmune and respiratory disorders	1.80%	Moderate	Europe, Asia Pacific	High	Mid Term
Growing adoption of corticosteroid therapies in critical respiratory care strengthening hospital demand volumes	1.50%	High	North America, Europe	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the corticosteroids market, supported by established prescribing patterns across respiratory, dermatology, rheumatology, and autoimmune care. Its leadership is strengthened by broad access to specialist-led diagnosis and treatment, which sustains steady product utilization across both acute and chronic inflammatory conditions. The region’s position is also underpinned by mature healthcare delivery systems and consistent patient access to branded and generic corticosteroid therapies, allowing demand to remain deeply embedded in routine clinical practice.

Asia Pacific is projected to expand at a 6.33% CAGR over the forecast period, with growth in the corticosteroids market being impelled by improving healthcare access and rising treatment uptake across large patient populations. Expansion is being driven in practice by greater diagnosis and management of inflammatory and allergic disorders, alongside wider availability of therapies through developing hospital and pharmacy networks. As care delivery capacity broadens across the region, corticosteroid use is accelerating in everyday treatment settings where affordability, accessibility, and volume adoption materially shape prescribing activity.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Nascent	Nascent
Cost-Sensitive Region	Medium	High	Medium	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Weak	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Dense	Sparse	Dense	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

Germany

Guideline-Based Prescribing

Germany emphasizes corticosteroid use aligned with established clinical guidelines and individualized patient management. Healthcare institutions in Germany focus on optimizing treatment protocols while encouraging careful monitoring to improve therapeutic outcomes and minimize adverse effects.

France

Responsible Therapeutic Use

France promotes corticosteroid prescribing practices that balance clinical benefits with long-term patient safety. Healthcare professionals in France increasingly emphasize evidence-based treatment selection, regular follow-up, and appropriate therapy adjustments across multiple therapeutic indications.

Italy

Hospital and Outpatient Balance

Italy maintains broad corticosteroid utilization across hospital care, specialty clinics, and outpatient treatment settings. Clinicians in Italy continue emphasizing individualized treatment plans, careful dose management, and appropriate formulation selection to support effective inflammatory disease control.

Japan

Specialized Therapy Optimization

Japan prioritizes corticosteroid formulations that support specialized treatment across inflammatory and immune-related conditions. Pharmaceutical companies in Japan continue improving formulation quality and delivery options to enhance patient adherence and clinical effectiveness.

South Korea

Advanced Treatment Integration

South Korea continues incorporating corticosteroids into multidisciplinary treatment pathways for chronic inflammatory disorders. Healthcare providers in South Korea increasingly favor optimized formulations and patient monitoring approaches that support effective disease management across clinical settings.

United States

Diverse Clinical Applications

The U.S. corticosteroids market is supported by broad therapeutic use across respiratory, dermatology, rheumatology, and autoimmune disease management. Healthcare providers in the U.S. increasingly balance treatment effectiveness with appropriate dosing strategies and long-term safety considerations.

Segment Leadership and Growth Trends

  Product Segment Analysis: Glucocorticoids (Largest Segment) vs Mineralocorticoids (Fastest-Growing Segment)

Glucocorticoids held the leading share of the corticosteroids market in 2025, reinforced through their broad use across inflammatory, autoimmune, allergic, and respiratory conditions where corticosteroid therapy is routinely prescribed. Their leadership is maintained through established prescribing familiarity, wide clinical applicability, and continued demand across both acute care and long-term disease management settings, which keeps Glucocorticoids at the center of product consumption in the corticosteroids market.

Mineralocorticoids represent the fastest-growing segment in the corticosteroids market as demand gains traction from treatment needs tied to hormone replacement and adrenal insufficiency management. Their growth momentum is tied less to broad-volume prescribing and more to the essential nature of use in specific endocrine care pathways, where consistent therapeutic necessity supports faster expansion relative to more mature corticosteroid product categories.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Online Pharmacies (Fastest-Growing Segment)

Hospital Pharmacies accounted for the largest share of the corticosteroids market in 2025, reflecting their central role in dispensing therapies used in inpatient treatment, emergency care, and specialist-led management of severe inflammatory and autoimmune conditions. This channel maintains leadership because corticosteroids are often initiated, adjusted, or monitored within hospital settings where physician oversight, immediate availability, and coordinated care remain critical to treatment delivery in the corticosteroids market.

Online Pharmacies are the fastest-growing distribution channel in the corticosteroids market, driven by the practical shift toward digital prescription fulfillment for repeat therapies and ongoing outpatient treatment. Their momentum is rising relative to traditional channels because they align with patient demand for convenience, home delivery, and easier refill access, particularly for chronic corticosteroid use where continuity and accessibility increasingly shape purchasing behavior.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Glucocorticoids, Mineralocorticoids	Glucocorticoids	Mineralocorticoids
Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies	Hospital Pharmacies	Online Pharmacies
Route of Administration	Oral, Topical, Inhaled, Injectable	Inhaled	Injectable
Application	Autoimmune Diseases, Skin Disorders, Respiratory Disorders, Allergic Conditions, Others	Respiratory Disorders	Autoimmune Diseases

Competitive Landscape and Market Positioning

Leading companies in the corticosteroids market:

1. Pfizer Inc. (U.S.)

2. Novartis AG (Switzerland)

3. AstraZeneca PLC (U.K.)

4. GSK plc (U.K.)

5. Merck KGaA (Germany)

6. Abbott Laboratories (U.S.)

7. Cipla Limited (India)

8. Eli Lilly and Company (U.S.)

9. Sanofi S.A. (France)

10. ReveraGen BioPharma Inc. (U.S.)

The corticosteroids market is progressing through continuous improvements in drug delivery systems, formulation technologies, and targeted therapeutic applications across inflammatory and respiratory conditions. Pharmaceutical companies are focusing on minimizing side effects while enhancing treatment effectiveness and patient adherence. Increased research into advanced corticosteroid therapies is also contributing to innovation within the corticosteroids market.

Industry Development/News

Company Name	Date	Key Development
GSK	Feb-26	GSK received European Commission approval for Exdensur, a twice-yearly treatment for severe asthma and chronic rhinosinusitis with nasal polyps. This authorization expands the company’s respiratory portfolio within the European market, following similar regulatory successes in the United States and Japan, and positions the biologic as a significant alternative to traditional corticosteroid-dependent treatment regimens.
GSK	Dec-25	The European Medicines Agency’s CHMP issued positive endorsements for GSK’s long-acting asthma therapy, depemokimab. This regulatory milestone supports the company’s strategic objective to capture market share in respiratory and inflammation care by transitioning patient treatment pathways toward high-value biologic therapies that offer clinical alternatives to conventional corticosteroid management.
Amgen, AstraZeneca	Oct-25	Amgen and AstraZeneca secured FDA approval for Tezspire in the treatment of chronic rhinosinusitis with nasal polyps. Following positive Phase III data demonstrating significant reductions in polyp severity, this label expansion broadens the biologic’s competitive footprint across inflammatory respiratory conditions, directly impacting the clinical utility of standard corticosteroid therapies.
Eli Lilly	Jul-25	Eli Lilly secured reimbursement-backed access for Ebglyss (lebrikizumab) in South Korea. This strategic move strengthens the company's position in the atopic dermatitis biologics segment, providing clinicians with a targeted alternative to corticosteroid-based therapies and potentially altering treatment patterns within the regional dermatology market.
LEO Pharma	Oct-24	LEO Pharma launched Anzupgo in Germany, representing the first approved topical treatment specifically indicated for chronic hand eczema. This launch marks a strategic expansion in the dermatology therapeutics market, aiming to capture volume from conventional corticosteroid treatments by offering a specialized therapeutic alternative for patients with localized inflammatory skin conditions.
Sanofi, Regeneron	Sep-24	Sanofi and Regeneron initiated plans to seek regulatory approval for Dupixent in treating bullous pemphigoid following successful Phase III trials. This development signifies a major effort to expand the biologic’s application into skin disorders historically reliant on systemic corticosteroid therapy, threatening to disrupt traditional clinical approaches for these inflammatory conditions.
LEO Pharma	May-24	LEO Pharma progressed its topical JAK inhibitor strategy with the development of delgocitinib cream. The product is positioned to compete directly in the atopic dermatitis market, diversifying therapeutic options and providing a non-corticosteroid alternative for patients requiring long-term topical inflammation management.
Ekuinas	Apr-24	Ekuinas acquired an 80% stake in pharmaceutical ingredients producer Symbiotica. This acquisition represents a strategic investment in the healthcare and drug ingredient manufacturing value chain, enhancing regional production capabilities and supply chain resilience for pharmaceutical participants operating within the broader medicine market, including those producing steroid-based therapeutics.